Skip to main content

Advertisement

Table 1 Clinical and pathological data of tissue and urine samples used in this study

From: MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

  Prostatectomies Urine samples
Clinicopathological data MNPT PCaa Controls PCab
Patients, n 15 180 46 95
Median age, years (range) 63
(45–80)
65
(49–74)
61
(58–77)
64
(45–80)
Median PSA (ng/mL) (range) - 8.3
(3.4-23.0)
- 8.8
(3.5-20.4)
Pathological Stage
pT2 (%) - 96 (53.3) - 46 (48.4)
pT3 (%) - 84 (46.7) - 49 (51.6)
Gleason score
<7 (%) - 56 (31.1) - 37 (39.0)
≥7 (%) - 124 (68.9) - 58 (61.0)
  1. aCohort #1; bCohort #3